Kronos Bio Inc (KRON) - Total Liabilities
Based on the latest financial reports, Kronos Bio Inc (KRON) has total liabilities worth $28.33 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Kronos Bio Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Kronos Bio Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Kronos Bio Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see KRON total assets.
Kronos Bio Inc Competitors by Total Liabilities
The table below lists competitors of Kronos Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Broendbyernes IF Fodbold AS
CO:BIF
|
Denmark | Dkr244.49 Million |
|
Shin Tai Industry Co Ltd
TW:1235
|
Taiwan | NT$2.40 Billion |
|
Melhus Sparebank
OL:MELG
|
Norway | Nkr10.35 Billion |
|
Petros Petropoulos AEBE
AT:PETRO
|
Greece | €69.41 Million |
|
Dongkuk Structures & Construction Company Limited
KQ:100130
|
Korea | ₩70.69 Billion |
|
Moberg Pharma AB (publ)
ST:MOB
|
Sweden | Skr17.04 Million |
|
Munjal Showa Limited
NSE:MUNJALSHOW
|
India | Rs1.87 Billion |
|
US Masters Residential Property Fund
AU:URF
|
Australia | AU$124.56 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Kronos Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Kronos Bio Inc to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kronos Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kronos Bio Inc (2018–2024)
The table below shows the annual total liabilities of Kronos Bio Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $36.78 Million | -32.14% |
| 2023-12-31 | $54.20 Million | +7.46% |
| 2022-12-31 | $50.44 Million | +8.75% |
| 2021-12-31 | $46.38 Million | -0.14% |
| 2020-12-31 | $46.45 Million | -63.11% |
| 2019-12-31 | $125.89 Million | +532.29% |
| 2018-12-31 | $19.91 Million | -- |
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT in… Read more